Dehexa peptide for memory and TBI: what the science says

What did @mindbodyneurology actually say?

The creator claims that a peptide called "the hexide" (Dihexa) is an oral capsule that "has been shown in studies to increase production of your BDNF," which they say allows the brain to "regenerate new cells" and improve connections between them. They go further, stating they use it in patients with cognitive dysfunction from brain injuries, Parkinson's, Alzheimer's, and "any other dimensions" (presumably dementias). The pitch is that Dihexa can "enhance your memory" and that this is backed by research.

To be clear: the creator does use the qualifier "theoretically" once, which is worth noting. But the overall framing, especially mentioning active clinical use in Alzheimer's and Parkinson's patients, leans heavily toward implied therapeutic benefit without adequate caveats about the evidence base.

Does the science back this up?

Sort of, but the gap between what exists in the literature and what's implied in this video is significant. Most Dihexa research is preclinical, meaning it was done in rodents, not humans. That matters enormously when you're talking about neurodegenerative diseases.

Dihexa (also written as PNB-0408 or N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) was developed by Joseph Harding and colleagues at Washington State University. Their 2013 paper in the Journal of Pharmacology and Experimental Therapeutics showed that Dihexa potently enhanced cognitive performance in scopolamine-impaired rats, outperforming BDNF itself in some hippocampal synaptogenesis assays (Harding et al., 2013, J Pharmacol Exp Ther). The mechanism involves hepatocyte growth factor (HGF) and its receptor c-Met, not direct BDNF upregulation, which is already a factual issue with what the creator said.

There are no published, peer-reviewed randomized controlled trials in humans. None. Animal data showing synaptic growth does not translate automatically to human memory enhancement, and the creator's framing skips over that entirely.

What did they get wrong (or right)?

The creator got the general premise partially right: Dihexa does appear to interact with pathways that support synaptic plasticity and neurogenesis in animal models. Credit where it's due. The connection to cognitive recovery mechanisms is a legitimate area of scientific interest.

But several things are wrong or imprecise. First, the mechanism. The creator says Dihexa increases BDNF. The actual research points to HGF/c-Met signaling as the primary pathway. BDNF and HGF both support neuroplasticity, but they are not the same thing, and conflating them misrepresents the science (Bhatt et al., 2020, Neural Regeneration Research).

Second, describing clinical use in Alzheimer's and Parkinson's patients based on animal data and no human trials is a serious overstep. These are vulnerable populations. Implying that Dihexa is an established option for neurodegeneration, even indirectly, is misleading.

Third, "any other dimensions" is clearly a mispronunciation of dementias, which is a minor verbal slip, but worth flagging for clarity.

What should you actually know?

Dihexa is not FDA-approved for any indication. It is not a regulated therapeutic in the United States. It is available through some compounding pharmacies and research chemical suppliers, which means quality control, dosing accuracy, and safety profiles are largely unknown in real-world use.

The excitement around Dihexa stems from genuinely interesting preclinical data. The 2013 Harding study showed roughly 10 million times more potent synaptogenic activity than BDNF in vitro. That number gets circulated a lot online. What gets left out is that potency in a cell culture assay or a rat model means very little until human pharmacokinetics, safety, and efficacy are established through trials.

There are also open questions about c-Met agonism at scale. Hepatocyte growth factor receptor signaling is involved in cell proliferation, and some researchers have raised theoretical concerns about oncogenic potential with chronic HGF pathway stimulation, though no direct evidence of this has been established for Dihexa specifically (Gherardi et al., 2012, Nature Reviews Cancer).

If you have a TBI or a neurodegenerative condition, the decision to try an unproven compound should happen with a physician who knows your full history, not based on a TikTok video that glosses over the absence of human trial data.